01Instil Bio (NASDAQ:TIL) will report Q2 2026 earnings on August 12, 2026 after market close, with analysts expecting a loss of $0.38 per share compared to breakeven in the prior year quarter.
02The company trades at $7.26 with a market capitalization of $75.1 million as a healthcare company.
03Recent earnings history shows the company has beaten estimates in consecutive quarters, with Q1 2026 delivering a $0.28 per-share beat and Q4 2025 delivering a $2.22 per-share beat.
Earnings Results
Instil Bio, Inc. (NASDAQ:TIL) is scheduled to report its Q2 earnings results on August 12, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.38, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $7.26 with a market capitalization of $75.1M.
Ahead of Instil Bio, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Instil Bio, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.